权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer

针对细胞周期改变改善晚期前列腺癌的治疗

基本信息

批准号：
9343456
负责人：
KAREN E KNUDSEN
金额：
$ 36.74万
依托单位：
THOMAS JEFFERSON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9343456
关键词：
Androgen Receptor Androgen Suppression Binding Biological Markers Biopsy Bypass CDK4 gene Castration Cell Cycle Cell Cycle Regulation Cells Chromatin Clinical Clinical Data Clinical Management Clinical Trials Collaborations Complement Complex Cyclin D1 Cyclin-Dependent Kinases Cytostatics Data Dependence Development Disease Disease Progression Disease Resistance Disease model Disease stratification Failure Funding Gene Expression Goals Growth Hypersensitivity Intervention Investigation Laboratories Link Malignant neoplasm of prostate Metastatic Prostate Cancer Modeling Molecular Molecular Profiling Pathway interactions Patient-Focused Outcomes Patients Phase I/II Trial Phenotype Phosphorylation Play Predisposition Production Recurrence Regimen Resistance Role Specificity Stratification Testing Therapeutic Therapeutic Intervention Treatment Efficacy Treatment Protocols Treatment outcome Up-Regulation actionable mutation advanced disease base cancer therapy castration resistant prostate cancer cytotoxic effective therapy experimental study gain of function hormone therapy human disease improved inhibitor/antagonist neoplastic cell novel outcome prediction personalized medicine pre-clinical precision medicine prevent prostate cancer cell receptor receptor expression resistance mechanism response response biomarker targeted cancer therapy targeted treatment therapeutic development therapy outcome treatment response treatment stratification tumor tumor progression

项目摘要

Abstract Recent advances in understanding progression to castration-resistant prostate cancer (CRPC) has led to development of therapeutics that slightly increase overall survival; however, the majority of patients with CRPC succumb to disease within 2-3 years, indicating the need for metrics of precision medicine, and development of additional therapeutics. Here, we propose an ambitious approach to stratify and enhance treatment for metastatic CRPC to improve therapeutic outcomes, based on cell cycle alterations that we recently discovered. The studies described will explore untouched territory with regard to PCa targeted therapy based management, and will provide the first assessment of treatment based on subtyping in this disease context. Moreover, the studies described could provide the first biomarker with which to stratify prostate cancer treatment, and to improve therapy for patients with advanced disease. Our collective findings strongly suggest that alterations in the RB-cyclin D1/CDK4 axis play major roles in disease progression, and molecular investigation of these alterations provide a rational basis for disease stratification and improved management of advanced PCa. This postulate will be challenged in carefully planned specific aim. First, building on 2 funded clinical trials, we will use biopsy material, novel models of disease, and co-clinical trials to challenge the hypothesis that the RB-cyclin D1/CDK4 axis can be developed as biomarkers of response and as metrics for treatment stratification (Aim 1). These studies have the potential for near-term patient benefit, and could identify the first biomarker for personalized medicine in advanced PCa. Second, robust models will be used to interrogate the molecular basis of responsiveness to therapeutic directed toward alterations in RB and/or cyclin D1 status (Aim 2). Studies planned will provide critical information as to specificity and clinical placement of RB and cyclin D1- alteration dependent interventions. Finally, targeting the Rb-cyclin D1/CDK4 axis forces reliance of tumor cells on G2/M cyclin dependent kinases—plans were thereby developed to leverage this cell cycle dependence, with a goal toward discovery of new means to maximize efficacy of treatment for cells with RB-cyclin D1/CDK4 alterations (Aim 3). These collective aims build off the unique collaboration amongst a leader in clinical management of advanced PCa and a pioneer of novel clinical trials (Dr. Kelly), and a leading AR biologist with significant expertise in studying cell cycle regulation and PCa-associated cell cycle alterations (Dr. Knudsen), and an expert in clinical targeting of cell cycle alterations (Dr. O’Dwyer). As proposed, this project has the capacity to illuminate the means by which perturbations Rb-cyclin D1 alterations alter disease progression and therapeutic response in human disease, and to dramatically alter PCa management.

摘要